Tafenoquine or SB-252263 is an 8-aminoquinoline and I have not checked if it has quinoloone side effects. Tafenoquine last a very long time in the body, so it does not need repeated doses.
A shorter regimen has also been described as an advantage.
The dose of tafenoquine is not set in stone, either for malaria or bbesia, but has not been firmly established, but 800 mg over three days has been used.
Amazingly, tafenoquine has been shown to be at least 10 times more potent than primaquine and has a much longer half-life, allowing less frequent dosing.
Antimicrob Agents Chemother. 1997 Jan;41(1):91-4.
Evaluation of selected antiprotozoal drugs in the Babesia microti-hamster model.
Marley SE, Eberhard ML,
Division of Parasitic Diseases, Centers for Disease Control and prevention, Department of Health and Human Services, Atlanta, Georgia 30341, USA.
The presently used therapy for Babesia microti infections, a combination of quinine and clindamycin, does not always result in parasitologic cures. To identify possible alternative we screened, in the hamster-B. microti system, 12 antiprotozoal drugs that have either recently been released for human use or were in experimental stages of development at the Walter Reed Army Institute of Research for the treatment of malaria and leishmaniasis. Several well-recognized antimalarial drugs, such as mefloquine, halofantrine, artesunate, and artelenic acid, exhibited little or no effect on parasitemia. Two 8-aminoquinolines, WR006026 [8-(6-diethylaminohexylamino)-6-methoxy-4-methylquinoline dihydrochloride] and WR238605 [8-[(4-amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5 -(3-trifluoromethylphenoxy-7) quinoline succinate], produced clearance of patent parasitemia. Furthermore, blood from infected hamsters treated with WR238605 via an intramuscular injection failed to infect naive hamsters on subpassage, thus producing a parasitologic cure. These two compounds merit further screening in other systems and may prove useful in treating human babesiosis.